Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside intervention

13 Feb 2015

Abstract excerpt

There is a growing awareness that complement plays an integral role in human physiology and disease, transcending its traditional perception as an accessory system for pathogen clearance and opsonic cell killing. As the list of pathologies linked to dysregulated complement activation grows longer, it has become clear that targeted modulation of this innate immune system opens new windows of therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Kawasaki Disease and Coronary Complications
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25678219
DOI: 10.1111/eci.12419

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside interventionPMID 25678219Read ↗

Compstatins: the dawn of clinical C3-targeted complement inhibitionSemantic proximity Read ↗

Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitorsSemantic proximity Read ↗

Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3.Semantic proximity Read ↗

Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacySemantic proximity Read ↗

Complement‐targeted therapeutics: An emerging field enabled by academic drug discoverySemantic proximity Read ↗

Complement‐targeted therapeutics: Are we there yet, or just getting started?Semantic proximity Read ↗

Structural insights into agonist-binding and activation of the human complement C3a receptorSemantic proximity Read ↗

Structure, function and control of complement C5 and its proteolytic fragments.Semantic proximity Read ↗

Developments in anti-complement therapy; from disease to clinical trialSemantic proximity Read ↗

A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug interventionSemantic proximity Read ↗

Complement C5 inhibition in patients with COVID-19 - a promising target?Semantic proximity Read ↗

The ‘C3aR antagonist’ SB290157 is a partial C5aR2 agonistSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.